Syros Reports Second Quarter 2023 Financial Results and Prov

-- On track to announce initial randomized data from SELECT-AML-1 trial in 4Q 2023 --


-- Expect to complete enrollment of 190 patients in SELECT-MDS-1 trial in 4Q 2023; pivotal CR data expected in...

Related Keywords

United States , American , Nancy Simonian , Syros Pharmaceuticals , See The Company , Exchange Commission , Pfizer , Linkedin , American Society For Clinical Oncology , Syros Pharmaceuticals Inc , Chief Executive Officer , Higher Risk Myelodysplastic Syndrome , Acute Myeloid Leukemia , Acute Promyelocytic Leukemia , Clinical Oncology , Annual Meeting , Private Securities Litigation Reform Act , Syro Annual Report , Quarterly Report , Markets ,